Cervical Cancer Diagnostic Market by Test Types (Pap Testing, HPV Testing, Colposcopy, Cervical Biopsies, and Cystoscopy) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021–2028

The global cervical cancer diagnostic market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the high prevalence of cervical cancer globally and ongoing R&D activities to improve cancer diagnostic technology and techniques.

Cervical cancer is one of the most common types of cancer that has caused several deaths globally. This type of cancer is widely prevalent among women and the number of the cases has been reported among women in the US. As per a study of 2016, the American Cancer Society stated that around 12,990 new cases of invasive cervical cancer were expected to be diagnosed and the number of the screening and diagnostics of cervical cancer were projected to increase rapidly in the coming years. According to a source, the women between 20 to 60 age group are more prone to this disease, however, the death rate of the cervical cancer was dropped by around 50% in the last four decades due to increasing adoption of screening procedure including Pap test and HPV testing.

According to the World Health Organization (WHO) statistics, around 270,000 women die every year owing to cervical cancer. The improper detection of the cervical cancer disease at an early stage leads to a higher mortality rate in developing economies. This leads to demand for advanced diagnostic devices that can offer high accuracy and effective in the detection of cancer. With the gradual development of new devices, the adoption of cervical cancer diagnostic tests is increased significantly.

Moreover, the introduction of various awareness programs is another key aspect of the market growth. For instance, Medicaid is a popular government insurance program that also covers the screening for cervical cancers and other related tests such as the pap test, pelvic exam, and clinical breast exam.

Market Drivers, Restraints, Trends, and Opportunities

• Favorable insurance reimbursement policies and wide number of cervical cancer cases especially in American women are the prime factors expected to propel the demand for screening tests during the forecast period.
• Recent technological advancements in the field of new diagnostic equipment, screening techniques, and diagnostic procedures are projected to positively impact the market growth.
• Growing awareness regarding the prevention, care, and treatment of cervical cancer as well as development of innovative biomarkers including long noncoding RNAs (lncRNA), mRNA, and m6A are propelling the market growth.
• The approvals of HPV vaccines by regulatory authorities is anticipated to hamper the growth of global cervical cancer diagnostic market during the forecast period. For instance, in 2016, the China Food and Drug Administration (CFDA) announced the approval of Cervarix, the first HPV vaccine licensed for use in China against cervical cancer. This helps in the prevention of cervical cancers among Chinese women.
• The emergence of the COVID-19 pandemic has created a huge burden on private healthcare sector. Additionally, it adversely affected the development, production, and supply of drugs across the world. This COVID-19 pandemic has negatively impacted the market growth.

Scope of Cervical Cancer Diagnostic Market Report

The report on the cervical cancer diagnostic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Cervical Cancer Diagnostic Market Segment Insights

Pap testing segment is projected to represent a considerable market share

On the basis of test types, the market is divided into pap testing or cytology testing, HPV testing, colposcopy, cervical biopsies, and cystoscopy. The pap testing segment is projected to represent a considerable market share during the forecast period owing to wide adoption of the test as it enables the diagnosis of abnormal cells of the cervix that might develop into cancer at a later stage. Moreover, the growth of the segment is attributed to the high efficiency of this test and growing awareness of people regarding early diagnosis of the disease.

The HPV testing segment, however, is expected to expand at an impressive CAGR during the forecast period due to the increasing demand for technically advanced diagnostics procedures at affordable cost. Additionally, recent development in the usage of several biomarkers and regular screening procedures are fueling the segment growth. Significant improvement in the accuracy and sensitivity of the screening tests are expected to spur the segment growth during the forecast period.

North America is expected to constitute a significant market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a significant market share during the forecast period owing to wide number of the cancer cases especially in the US. The increasing prevalence of cervical cancer among women in the US coupled with growing awareness regarding early diagnosis of disease are projected to boost the regional market growth.

In the US, Hispanic women are more susceptible of developing cervical cancer, which is followed by women of Pacific-Islanders, White women, and Afro-American. However, American Indians and Alaskans are projected to be at a lower risk of developing this disease. The market in Asia Pacific, however, is projected to expand at a healthy CAGR during the forecast period owing to the substantial growth in the diagnostic rate and favorable government initiatives encouraging the early detection of the cancer type.

Segments

The global cervical cancer diagnostic market has been segmented on the basis of

Test Types

• Pap Testing or Cytology Testing
• HPV Testing
• Colposcopy
• Cervical Biopsies
• Cystoscopy

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key players

• Abbott Laboratories
• Cooper Surgical Inc.
• Becton Dickinson and Company (BD)
• Hologic, Inc.
• Quest Diagnostics
• QIAGEN
• Guided Therapeutics
• Siemens
• OncoHealth Corp.
• Arbor Vita
• Zilico Ltd.
• Beckman Coulter Inc.

Competitive Landscape

Some of the prominent players in the global cervical cancer diagnostics market include Abbott Laboratories, Cooper Surgical Inc., Becton, Dickinson and Company (BD), Hologic, Inc., Quest Diagnostics, QIAGEN, Guided Therapeutics, Siemens, OncoHealth Corp., Arbor Vita, Zilico Ltd., and Beckman Coulter Inc.

The companies are focusing on the technological advancements of the diagnostic techniques, which include liquid-based cytology. For instance, in 2014, F. Hoffmann-La Roche Ltd. introduced a full automated CINtec PLUS cytology test for removal of the unhealthy tissue from the cervical site prior to the development of cancer tissue. Furthermore, the company had received a US FDA’s approval for Avastin, which is a biologic medicine plus chemotherapy for treatment of advanced cervical cancer patients.